Arrowhead Pharmaceuticals’ (ARWR) “Buy” Rating Reiterated at Chardan Capital

Chardan Capital restated their buy rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) in a research report released on Monday,Benzinga reports. They currently have a $115.00 price target on the biotechnology company’s stock.

ARWR has been the topic of several other research reports. B. Riley Financial lifted their target price on Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. HC Wainwright increased their price target on shares of Arrowhead Pharmaceuticals from $115.00 to $120.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Leerink Partners raised their price target on shares of Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the company a “market perform” rating in a report on Wednesday, June 17th. Stifel Nicolaus assumed coverage on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, July 14th. They issued a “buy” rating and a $98.00 price objective on the stock. Finally, Wall Street Zen upgraded shares of Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, June 27th. Nine investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Arrowhead Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $98.42.

Arrowhead Pharmaceuticals Stock Up 3.2%

Shares of NASDAQ ARWR opened at $85.37 on Monday. The company has a current ratio of 5.90, a quick ratio of 5.90 and a debt-to-equity ratio of 1.77. The stock has a market capitalization of $12.03 billion, a PE ratio of -37.94 and a beta of 1.28. The stock’s fifty day simple moving average is $83.82 and its two-hundred day simple moving average is $74.07. Arrowhead Pharmaceuticals has a 12-month low of $25.61 and a 12-month high of $95.49.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.13). The company had revenue of $75.25 million during the quarter, compared to analysts’ expectations of $44.17 million. Arrowhead Pharmaceuticals had a negative net margin of 47.79% and a negative return on equity of 60.06%. The company’s revenue was up 171.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.26) earnings per share. As a group, analysts expect that Arrowhead Pharmaceuticals will post -3.62 EPS for the current fiscal year.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, Director Adeoye Y. Olukotun sold 2,000 shares of the stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $86.96, for a total value of $173,920.00. Following the completion of the sale, the director directly owned 31,600 shares in the company, valued at approximately $2,747,936. This trade represents a 5.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Michael S. Perry sold 11,600 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $87.30, for a total value of $1,012,680.00. Following the completion of the sale, the director directly owned 111,459 shares of the company’s stock, valued at approximately $9,730,370.70. This represents a 9.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 3.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

Several hedge funds have recently modified their holdings of ARWR. Tsfg LLC acquired a new stake in Arrowhead Pharmaceuticals in the 4th quarter worth approximately $25,000. Optiver Holding B.V. grew its position in Arrowhead Pharmaceuticals by 83.8% during the 1st quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 186 shares during the last quarter. Versant Capital Management Inc grew its position in Arrowhead Pharmaceuticals by 285.1% during the 2nd quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 248 shares during the last quarter. Carolina Wealth Advisors LLC increased its stake in Arrowhead Pharmaceuticals by 80.6% during the 2nd quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 154 shares in the last quarter. Finally, iSAM Funds UK Ltd acquired a new position in Arrowhead Pharmaceuticals during the 3rd quarter valued at approximately $29,000. Institutional investors and hedge funds own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.